^
    Back
    Association details:
    Biomarker:FGFR3 overexpression
    Cancer:Head and Neck Cancer
    Drug:rogaratinib (BAY 1163877) (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2018
    Title:

    Phase I experience with rogaratinib in patients with head and neck cancer selected based on FGFR mRNA overexpression

    Published date:
    10/01/2018
    Excerpt:
    Pts were treated with rogaratinib 800 mg twice daily until tumor progression,...Seven of 10 patients overexpressed FGFR3 mRNA subtype, including both patients with a PR.
    DOI:
    https://doi.org/10.1093/annonc/mdy287.012
    Trial ID:
    NCT01976741; NCT02592785